A pharmaceutical company reveals its priorities in the careers it makes possible.
An experienced analyst should not have to become a reluctant line manager to earn recognition for deeper technical work. A quality leader should know who will hear a disagreement when the production calendar becomes difficult. A new manufacturing line needs more than an approved headcount. These questions connect careers, authority and operating capacity. They are where I have spent much of my working life, first in factory personnel and now as the fictional CHRO of Anvethra Pharmaceuticals.
Our India-based business develops and manufactures oral-solid formulations. It employed 4,600 people at the end of March 2026 across three manufacturing locations, a development centre and commercial functions. I lead seventy-four people colleagues through six direct reports. My responsibility is to connect the organisation and employment decisions with the technical work, without pretending that the people function can make a scientific assessment or release a batch.
I am interested in the gap between an approved organisation chart and the experience of holding a role. Does a specialist have a credible future? Can a supervisor decline work that exceeds the capability available? Does the quality function have access to the person who can resolve an organisational disagreement? My record includes decisions that cost more or took longer than planned, and one reward experiment I helped reverse. Those consequences are more useful than a broad claim that culture improved.
Technical progression acquired an actual pay and role structure
A 2021 specialist-career review covered 84 formulation and analytical colleagues. Eighteen moved into assessed specialist grades without taking line-management duties. The approved annual pay effect was ₹1.26 Cr. The remaining sixty-six stayed in their current grades with written feedback; the exercise was not presented as a universal promotion.
An expansion timetable changed when experience could not be copied
For a 2023 line expansion, a proposed transfer of twenty-four experienced colleagues would have weakened the existing unit. We agreed twelve transfers and twelve external hires, with ₹2.4 Cr for staged overlap and preparation. The revised start moved six weeks. Technical leaders retained responsibility for authorising work.
An incentive was withdrawn when its signal proved harmful
In 2014, I supported an attendance-linked supervisor award. Employee discussions showed that it discouraged timely reporting of illness. We withdrew that criterion, reassessed forty-one awards and changed thirteen decisions. The ₹19 lakh correction was recorded as the cost of our original design, not a workforce success statistic.
Current focus
My 2026 review examines twelve specialist appointments made during the previous two years. Nine have written evidence of the technical contribution expected at their grade; three need clearer role definitions. I am working with functional leaders on those three cases before proposing another expansion of the career structure. A title should create a usable responsibility, not merely settle a retention conversation.
Conversations I welcome
I am open to a people-leadership or advisory mandate in a pharmaceutical business willing to examine the relationship between technical authority, careers and investment decisions. I would consider a first external board appointment with an appropriate induction and a clearly defined contribution. For speaking, I prefer a working discussion of one employment decision and its consequences to a general address on inspiration.